BioNTech stock trades at EUR 86.05 after a revenue miss

Published on 09/30/2026 at 17:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech stock reported Q2 2026 revenue of EUR 105.6 million, down from EUR 260.8 million. Berenberg raised its target to USD 140.00 on September 16, 2026.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech (ISIN US09075V1026) was trading at EUR 86.05 at Lang & Schwarz on September 30, 2026 at 4:43 p.m. CEST, down 0.90 percent versus the prior close of EUR 86.83. The latest quarterly figures show why the stock remains tied to the companys transition from COVID vaccine revenue toward oncology growth.

Revenue fell 59.50 percent

For the quarter ending June 30, 2026, BioNTech reported revenue of EUR 105.6 million, compared with EUR 260.8 million in the year-earlier quarter, according to The Globe and Mail. That 59.50 percent decline came with a GAAP net loss of EUR 820.8 million, versus EUR 386.6 million a year earlier.

The weak quarter also missed expectations. MarketBeat reported adjusted loss per share of USD 2.53 against a USD 2.40 consensus estimate and revenue of USD 122.31 million against USD 180.18 million for the quarter.

Guidance reset meets oncology test

BioNTech reduced its full-year 2026 revenue guidance to EUR 1.6 billion to EUR 1.9 billion from EUR 2.0 billion to EUR 2.3 billion, as reported by Yahoo Finance. The lower range puts greater weight on pipeline progress and partnership revenue to offset weaker COVID vaccine demand.

The clinical pipeline also carries a direct risk signal. BioNTech and Genentech terminated a Phase 2 colorectal cancer trial for autogene cevumeran on August 28, 2026, after the study crossed a futility threshold, according to Yahoo Finance. The decision narrows one development path while the wider oncology portfolio remains central to the investment case.

Analyst target moved to USD 140

Berenberg raised its BioNTech price target from USD 132.00 to USD 140.00 and kept a Buy rating on September 16, 2026, according to MarketScreener. MarketBeat reported a broader average target of USD 126.00 and a Moderate Buy consensus, although the estimate range shows differing views on the pace of BioNTechs recovery.

Market data put BioNTechs market capitalization at USD 24.7 billion on September 30, 2026, with a 52-week range of USD 79.52 to USD 124.00. The stock was 30.60 percent below its 52-week high, leaving the next earnings update and oncology data as measurable tests for the revised outlook.

Stock trades below prior close

BioNTech was trading at EUR 86.05 at Lang & Schwarz on September 30, 2026 at 4:43 p.m. CEST, down 0.90 percent against the Lang & Schwarz prior close of EUR 86.83 on September 29, 2026. The further course of trading is shown by the continuously updated real-time quote of BioNTech stock.